Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC raised its position in Replimune Group, Inc. (NASDAQ:REPL) by 139.1% in the 2nd quarter, Holdings Channel reports. The fund owned 29,344 shares of the company’s stock after acquiring an additional 17,072 shares during the period. Hsbc Holdings PLC’s holdings in Replimune Group were worth $253,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. lifted its position in Replimune Group by 17.6% in the second quarter. American Century Companies Inc. now owns 50,785 shares of the company’s stock valued at $457,000 after purchasing an additional 7,587 shares during the period. Quest Partners LLC lifted its holdings in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Replimune Group by 63.2% in the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock valued at $1,668,000 after buying an additional 71,867 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after acquiring an additional 5,410 shares during the period. Finally, Arizona State Retirement System purchased a new position in Replimune Group in the second quarter worth $108,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Down 1.1 %

REPL stock opened at $11.56 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The company’s 50 day simple moving average is $10.48 and its 200-day simple moving average is $8.62. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $16.70. The firm has a market capitalization of $789.78 million, a PE ratio of -3.57 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Equities analysts expect that Replimune Group, Inc. will post -3.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

REPL has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Barclays lifted their price target on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average price target of $16.80.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 20.60% of the stock is currently owned by company insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.